The E296V and M298Q mutations gave an increased intrinsic amidolytic activity about two- and 3.5-fold, respectively compared with wild-type FVIIa.. Compared with wild-type FVIIa, the Ca2
Trang 1Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes
Egon Persson1and Ole H Olsen2
1
Haemostasis Biology and2Medicinal Chemistry Research IV, Novo Nordisk A/S, Ma˚løv, Denmark
The most active factor VIIa (FVIIa) variants identified to
date carry concurrent substitutions at positions 158, 296and
298 with the intention of generating a thrombin-mimicking
motif, optionally combined with additional replacements
within the protease domain [Persson, E., Kjalke, M &
Olsen, O H (2001) Proc Natl Acad Sci USA 98, 13583–
13588] Here we have characterized variants of FVIIa
mutated at one or two of these positions to assess the relative
importance of the individual replacements The E296V and
M298Q mutations gave an increased intrinsic amidolytic
activity (about two- and 3.5-fold, respectively) compared
with wild-type FVIIa An additive effect was observed upon
their combination, resulting in the amidolytic activity of
E296V/M298Q-FVIIa being close to that of the triple
mutant The level of amidolytic activity of a variant was
correlated with the rate of inhibition by antithrombin (AT)
Compared with wild-type FVIIa, the Ca2+dependence of
the intrinsic amidolytic activity was significantly attenuated
upon introduction of the E296V mutation, but the effect was
most pronounced in the triple mutant Enhancement of the proteolytic activity requires substitution of Gln for Met298 The simultaneous presence of the V158D, E296V and M298Q mutations gives the highest intrinsic activity and is essential to achieve a dramatically higher relative increase in the proteolytic activity than that in the amidolytic activity The N-terminal Ile153 is most efficiently buried in V158D/ E296V/M298Q-FVIIa, but is less available for chemical modification also in the presence of the E296V or M298Q mutation alone In summary, E296V and M298Q enhance the amidolytic activity and facilitate salt bridge formation between the N-terminus and Asp343, E296V reduces the
Ca2+dependence, M298Q is required for increased factor X (FX) activation, and the simultaneous presence of the V158D, E296V and M298Q mutations gives the most pro-found effect on all these parameters
Keywords: factor VIIa variant; factor X activation; intrinsic activity; superactivity; zymogenicity
Coagulation factor VIIa (FVIIa), in contrast to other,
homologous serine proteases, possesses an active
confor-mation that is energetically unfavourable The consequence
is a far from optimal enzymatic activity of free FVIIa, which
is dramatically enhanced upon binding to the cognate,
membrane-bound cofactor tissue factor (TF) or to its
extracellular, soluble portion (sTF) [1] In the natural
environment, the zymogenicity of free FVIIa ensures timely
triggering and appropriate location of FVIIa haemostatic
activity upon vascular lesion and concomitant TF exposure
The three-dimensional structure of the protease domain
of free FVIIa is, apart from certain loop regions, virtually
identical to that of thrombin and other constitutively active
and homologous serine proteases [2,3] In addition, the
structural differences between free [3–5] and TF-bound
FVIIa [6,7] are subtle; thus the details in molecular
architecture that restrict the activity of free FVIIa remain
elusive However, the high degree of similarity may be due
to the presence of an active site inhibitor in the structure of the free FVIIa The crystal (or solution) structure of noninhibited FVIIa is presumably needed to reveal the structural differences between latent (zymogen-like) and
active FVIIa However, information possibly pertaining to the latent conformation of free FVIIa has been obtained from the crystal structure of zymogen FVII [8] This structure suggests that relative b strand movements and a hydrogen bond involving Glu296{154} (chymotrypsinogen numbering is given in curly brackets to facilitate compar-isons with homologous enzymes) regulate the activity state
of FVIIa
Recent advances in our understanding of the mechanisms regulating the activity of FVIIa have pinpointed side chains that function as zymogenicity determinants in the free enzyme Replacements of these amino acid residues have resulted in FVIIa molecules with improved intrinsic (TF-independent) catalytic efficiency [9–11] The relatively high intrinsic activity of some of these FVIIa variants suggests that the zymogen-like conformation of free factor VIIa is dictated by a limited number of key amino acid residues We have previously shown that one of these superactive FVIIa variants, containing the mutations V158{21}D, E296{154}V and M298{156}Q, exhibits several properties resembling TF-bound rather than free FVIIa [9] Apart from increased intrinsic enzymatic activity and inhibitor susceptibility as compared with wild-type FVIIa, this mutant has a diminished requirement for calcium ions and a more deeply buried protease domain N-terminus
Correspondence to E Persson, Haemostasis Biology, Novo Nordisk
A/S, Novo Nordisk Park, DK-2760 Ma˚løv, Denmark.
Fax: + 45 44434417, Tel.: + 45 44434351,
E-mail: egpe@novonordisk.com
Abbreviations: FVIIa, coagulation factor VIIa; FX, coagulation factor
X; sTF, soluble tissue factor (residues 1–219); TF, tissue factor;
AT, antithrombin (III).
(Received 20 June 2002, revised 2 October 2002,
accepted 22 October 2002)
Trang 2(Ile153{16}) indicating salt bridge formation of this residue
with Asp343 {194} To pinpoint the underlying mutation(s)
responsible for these molecular and functional properties of
the triple mutant, and thereby gain more knowledge about
the zymogenicity determinants of FVIIa, mutants with
substitutions at one or two of positions 158{21}, 296{154}
and 298{156} were expressed and characterized
M A T E R I A L S A N D M E T H O D S
Proteins, chemical reagents and standard methods
Wild-type FVIIa [12] and sTF [13] were prepared according
to published procedures The concentrations of FVIIa and
sTF were determined by ELISA and spectrophotometry,
respectively, as described [9] SDS/PAGE was run on
8–25% gradient gels using the PhastSystem (Amersham
Pharmacia) and followed by silver staining to check the
purity of the FVIIa mutants and to verify their conversion
to the activated, two-chain form Factor X (FX) and factor
Xa were from Enzyme Research Laboratories (South Bend,
IN, USA) and antithrombin (AT) from Hematologic
Technologies (Essex Junction, VT, USA) Unfractionated
heparin was from Leo Pharmaceutical Products (Ballerup,
Denmark), potassium cyanate (KOCN) from Merck and
the chromogenic substrates S-2288 (D
-Ile-Pro-Arg-p-nitro-anilide) and S-2765 (benzyloxycarbonyl-D
-Arg-Gly-Arg-p-nitroanilide) from Chromogenix (Mo¨lndal, Sweden)
Mutagenesis and preparation of FVIIa mutants
The FVII expression plasmid pLN174 [14] was used as the
template for site-directed mutagenesis using the
Quik-Change kit (Stratagene, La Jolla, CA, USA) The primer
(only sense primer is given) used to introduce the E296V
mutation, with base substitution in italic and the affected
codon underlined, was GCC ACG GCC CTG GTG CTC
ATG GTC CTC The primers used to introduce the V158D,
E296V/M298Q and M298Q mutations have been described
[9] Plasmid preparation, baby hamster kidney cell
trans-fection and selection, and the expression, purification and
autoactivation of FVII mutants were carried out as
described [9,15] The presence of none but the desired
mutation(s) was verified by sequencing the portion of the
cDNA encoding residues 80–406, encompassing the
second epidermal growth factor-like and serine protease
domains, on a MegaBACE 1000 (Amersham Pharmacia
Biotech)
Activity and inhibition assays
The enzymatic activity and inhibition rates of the FVIIa
variants were measured as described [9] using an assay
buffer containing 50 mMHepes, 0.1MNaCl, 5 mMCaCl2
and 1 mgÆmL)1bovine serum albumin (pH 7.4) Briefly, the
amidolytic activity was measured by mixing 180 lL
wild-type or mutant FVIIa alone (final concentration 100 nM) or
180 lL FVIIa together with sTF (final concentrations
10 nMFVIIa and 50 nMsTF) with 20 lL 10 mMS-2288 at
25C The measurement with free FVIIa was also
per-formed in an assay buffer where CaCl2 was replaced by
EDTA The ability of the FVIIa variants to activate FX (the
proteolytic activity) was studied by incubating 10 n
(M298Q-, V158D/M298Q-, E296V/M298Q- and V158D/ E296V/M298Q-FVIIa) or 50 nM (wild-type, V158D-, E296V-, and V158D/E296V-FVIIa) FVIIa variant alone
or 5 nM FVIIa variant plus 100 nM sTF with various concentrations of FX (0.1–4.8 lM) for 20 min at ambient temperature (22 ± 1C) Buffer containing S-2765 was then added to give a chromogenic substrate concentration
of 0.5 mM, whereafter the factor Xa-catalyzed hydrolysis was measured for 2 min The inherent activity of the FX substrate and of the FVIIa/sTF mixture were subtracted and the net amount of factor Xa generated was derived from a standard curve The kinetic parameters of FX activation were calculated using GRAFIT 4.06(Erithacus Software, Ltd) The rates of inhibition by AT/heparin and potassium cyanate were studied according to published methods [9] by incubation of the FVIIa variants (100 nM with AT and 1 lMwith cyanate) with the inhibitor for 15 and 60 min, respectively, followed by measurements of the residual amidolytic activity Bovine serum albumin was omitted from the buffer during the incubation with cyanate
R E S U L T S
Enzymatic activity of FVIIa variants Two forms of enzymatic activity are analyzed The amido-lytic activity is measured to assess the functional status of the active site, whereas the proteolytic activity reflects both this and exosite alterations resulting in further increased macromolecular substrate turnover In the absence of TF, V158D/E296V/M298Q-FVIIa has seven- to eight-fold higher intrinsic amidolytic activity compared with wild-type FVIIa as measured by the rate of hydrolysis of the chromogenic substrate S-2288 [9] When the mutations were introduced individually into FVIIa, V158D had no significant effect on the amidolytic activity, whereas E296V and M298Q yielded approximately two- and 3.5-fold enhancement, respectively (Table 1) The result with M298Q-FVIIa agrees with earlier reports [9,10] The double mutant E296V/M298Q-FVIIa had an amidolytic activity six times higher than that of wild-type FVIIa and close to that of V158D/E296V/M298Q-FVIIa In addition, V158D/ E296V-FVIIa had significantly lower amidolytic than E296V-FVIIa and V158D/M298Q-FVIIa had similar or slightly lower activity than M298Q-FVIIa This shows that the simultaneous presence of the E296V and M298Q mutations suffices to achieve an amidolytic activity similar
Table 1 Enzymatic activity of free FVIIa variants All values are means ± SD (n ¼ 3) The amidolytic activity is given as the ratio between the activity of mutant and wild-type FVIIa.
FVIIa variant
Amidolytic activity (mutant/wt)
FX activation (k cat , · 10)3s)1)
V158D/E296V/M298Q 7.6 ± 0.5 2.2 ± 0.3
Trang 3to that of the triple mutant and that the substitution of Asp
for Val at position 158 has an insignificant or negative
impact on the amidolytic activity In complex with sTF,
none of the investigated mutants had an amidolytic activity
significantly different from that of wild-type FVIIa (not
shown)
The amidolytic activity of free FVIIa has been shown to
be at least about 10 times higher in the presence of 5 mM
Ca2+ than in the absence of the metal ion [16,17] As
expected, in the absence of Ca2+wild-type FVIIa exhibited
an amidolytic activity corresponding to about one tenth of
its activity in the presence of 5 mMCa2+ This was also the
case for V158D-FVIIa, M298Q-FVIIa and
V158D/M298Q-FVIIa In contrast, all FVIIa variants containing the E296V
mutation retained a larger fraction of their activity when
Ca2+ was omitted from the assay buffer; E296V-FVIIa
(retained 24% of the activity), V158D/E296V-FVIIa (29%),
E296V/M298Q-FVIIa (39%) and, in particular, V158D/
E296V/M298Q-FVIIa (64%) This shows that the
substitu-tion of Val for Glu296{154}, which contacts the acidic Ca2+
binding loop in the protease domain, attenuates the Ca2+
dependence of FVIIa and confirms that this replacement is
responsible for the diminished Ca2+requirement observed
for V158D/E296V/M298Q-FVIIa [9] The additional
sub-stitution of Gln for Met298{156}, especially in combination
with the replacement of Val158{21} by Asp, further
attenuates the Ca2+dependence
We have previously shown that, in the absence of TF, the
kcatvalues for FX activation by M298Q-FVIIa and V158D/
E296V/M298Q-FVIIa were increased 5.5- and 28-fold
compared with that of wild-type FVIIa, respectively [9] In
agreement with these results, the new batches of the two
variants displayed seven- and 25-fold higher values,
respect-ively (Table 1) E296V/M298Q-FVIIa and
V158D/M298Q-FVIIa activated FX five to seven times more rapidly than
did wild-type FVIIa, rates similar to that seen with
M298Q-FVIIa This indicates that the introduction of the V158D or
E296V mutation on the M298Q-FVIIa background does
not contribute to an increased proteolytic activity Indeed,
an increased rate of FX activation was only observed for the
FVIIa variants containing the M298Q mutation, and
V158D-FVIIa, E296V-FVIIa and V158D/E296V-FVIIa
exhibited a rate of catalysis of FX activation similar to or
slightly below that of wild-type FVIIa It is noteworthy that
FX activation occurs much faster when catalyzed by
V158D/E296V/M298Q-FVIIa than when catalyzed by
V158D/E296V-FVIIa, V158D/M298Q-FVIIa or E296V/
M298Q-FVIIa This suggests that the triad composed of
residues 158{21}, 296{154} and 298{156} works as a unit
regulating macromolecular substrate processing by free
FVIIa All FVIIa variants (including the wild-type enzyme)
gave Kmvalues for FX between 2.2 and 2.8 lMindicating
that the mutations did not affect substrate affinity to a
detectable extent (data not shown) When bound to sTF,
none of the studied FVIIa variants exhibited an increased
ability to activate FX as compared with wild-type FVIIa
(not shown)
Inhibition of FVIIa variants by antithrombin
and potassium cyanate
The susceptibility of the FVIIa variants to inhibition by
two mechanistically different agents, antithrombin (active
site-directed) and potassium cyanate (N-terminal carbamy-lation), was investigated The rate of inhibition by anti-thrombin reflects the reactivity of the active site and has previously been found to nicely correlate to the level of amidolytic activity of FVIIa variants [9] The results herein show that the new variants also obey this rule, with a strong relationship between amidolytic activity enhancement and increased inhibition rate (Table 2) The inhibition resulting from potassium cyanate-mediated, N-terminal carbamyla-tion reflects the degree of exposure of the protease domain N-terminus When compared with that of wild-type FVIIa, the susceptibility to carbamylation was found to be strikingly reduced for V158D/E296V/M298Q-FVIIa (and reduced to some extent also for M298Q-FVIIa) indicative of
a more buried N-terminal amino group [9] A majority
of the present FVIIa variants exhibits an intermediate level
of protection from carbamylation (Table 2) E296V-FVIIa retains about half of its activity after incubation with potassium cyanate, which is slightly more than wild-type FVIIa V158D/E296V-FVIIa, V158D/M298Q-FVIIa and E296V/M298Q-FVIIa all retain about 60% of their activity, which is similar to the residual activity of M298Q-FVIIa but considerably less than that of V158D/E296V/M298Q-FVIIa This indicates that no single mutation is particularly efficient in terms of promoting the insertion of the N-terminus and, importantly, demonstrates that all three mutations are needed for stable burial of the N-terminus, most likely through salt bridge formation with Asp343{194})
D I S C U S S I O N
V158D/E296V/M298Q-FVIIa has been found to possess unique properties that differ dramatically from those of wild-type FVIIa (Fig 1) This includes an increased intrinsic activity, a reduced activity dependence on Ca2+ and a buried protease domain N-terminus [9] The characteriza-tion of FVIIa variants containing one or two of the mutations at positions 158{21}, 296{154} and 298{156} has enabled the identification of the amino acid changes mainly responsible for the unique profile of the triple mutant M298Q is the single mutation that enhances the amidolytic activity to the largest extent The E296V mutation, on the other hand, appears to be responsible for the decreased calcium ion dependence of the amidolytic activity, with the other two mutations functioning as modulators of this
Table 2 Inhibitor susceptibility of free FVIIa variants The residual activity (%) after incubation with the inhibitor for 15 min (anti-thrombin) and 60 min (KNCO) is given (means ± SD, n ¼ 3).
FVIIa variant
Inhibitor
Trang 4property in the presence of valine at position 296 It is
possible that the increased activity of FVIIa after Ca2+
binding to the acidic 210–220 {70–80} loop [18] is induced,
at least to some extent, by a conformational change
resulting from charge neutralization The altered local
charge distribution upon replacement of Glu296by Val
might in part mimic this effect and contribute to an
increased activity and reduce the positive effect of Ca2+
binding (Fig 1A) The relative intrinsic proteolytic activity,
i.e the degree of enhanced catalysis of FX activation,
follows a pattern slightly different from that of the
amidolytic activity The M298Q mutation, in contrast to
V158D and E296V, enhances the proteolytic activity and is
indeed present in all members of this family of FVIIa
variants with increased proteolytic activity Moreover,
V158D/E296V/M298Q-FVIIa is far superior to the other
variants, indicating that the three mutations work together
in a concerted fashion to dramatically boost the proteolytic
activity The fact that FX itself binds Ca2+precludes direct
studies of the influence of Ca2+on the proteolytic activity
An intriguing property of V158D/E296V/M298Q-FVIIa is the nonparallel increase in amidolytic and proteolytic activity compared with wild-type FVIIa Such a behaviour, but less pronounced, is also observed for M298Q- and V158D/M298Q-FVIIa This demonstrates that the three mutations together, and to some extent the M298Q mutation alone, somehow result in an additional facilitation
of macromolecular substrate processing on top of the activity increase detected with a low-molecular-mass, chromogenic substrate The V158D and E296V mutations need to be present simultaneously to achieve a proteolytic activity higher than that observed with M298Q-FVIIa This indicates that local net charge and charge distribution are critical, presumably in order to allow for a stable local conformation to involve in an exosite interaction with FX
A recent study has clearly shown that the charge on residue
158 is pivotal for enhanced FX activation [19] The relative rate of hydrolysis of peptides of various lengths (from
Fig 1 Activation pocket region of FVIIa (A) The carbon atoms of the N-terminal residues 153{16} to 158{21} are shown in green, those of b strand B2 in the active FVIIa conformation (residues 296{154} to 305{163}) in gray and in the zymogen or inactive conformation (residues 296{154} to 302{160}) in magenta, and the Ca2+binding loop (residues 210{70} to 220{80}) is shown as a gray ribbon with the Ca2+ion represented by a magenta sphere The residues in position 158{21} and in positions 296{154} and 298{156} in the active B2 conformation are those found in V158D/ E296V/M298Q-FVIIa The water molecule interacting with the backbone carbonyl of Ile153{16}, the backbone amides of residues 155{18} and 156{19} and the side chain of Gln298{156} is shown as a red sphere (B and C) Detail of the activation pocket in V158D/E296V/M298Q-FVIIa and wild-type FVIIa, respectively The structure is from the FVIIa-TF complex (6, PDB entry code 1dan), except for the zymogen conformation of strand B2 which is from the structure of FVII (8, PDB entry code 1jbu) The drawings were made using QUANTA 2000 (Accelrys Inc.).
Trang 5P4-P1¢ to P4-P7¢ of FX) by V158D/E296V/M298Q-FVIIa
as compared with that of wild-type FVIIa was constant,
indicative of that the three mutations do not simply increase
the accessibility of the substrate binding cleft to longer
substrates (E Persson, A M Hansen, K Madsen and O
H Olsen, unpublished observation) However, the peptides
may not correctly mimic the corresponding sequences when
part of FX Finally, the high proteolytic activity of V158D/
E296V/M298Q-FVIIa appears to be accompanied by a
stabilized salt bridge between Ile153{16} and Asp343{194}
Crystallographic data and molecular dynamics
simula-tions of FVII suggest that the purpose of the activation to
FVIIa is to maturate and open the substrate binding site, in
particular the S1 pocket, whereas an appropriate catalytic
triad geometry appears to be preformed in the zymogen
[8,20] However, even after conversion to FVIIa the
conformational equilibrium appears to be shifted toward
an enzymatically latent form Thus, the role of TF, apart
from localizing FVIIa to the site of vascular injury,
optimally positioning the active site [21] and contributing
to an extended, specificity-determining, factor IX/X binding
surface [22–24], is to stabilize the active FVIIa
conforma-tion Strong evidence supports that Met306in FVIIa is the
starting point for the TF-mediated effect on the FVIIa
conformation leading to allosteric stimulation of the
enzymatic activity [6,15,25,26] Recently, site-directed
muta-genesis on FVIIa has been able to mimic the effect of TF
binding, at least in part, resulting in FVIIa molecules with
enhanced intrinsic activity [9–11,19] Two published
hypo-theses accommodate an instrumental role of the activation
region in the regulation of the activity of free FVIIa, the first
dealing with the structural requirements for FVIIa to be in
an active conformation [8], whereas the other tries to explain
the effects of the activity-enhancing mutations [9] They are
complementary and contribute to our understanding of
how the activity-enhancing mutations in this region of
FVIIa might exert their influence on the enzymatic activity
Replacement of Met298{156} by Gln could prevent relative
b strand movement and stabilize strand B2 in a position
compatible with an active FVIIa conformation (Fig 1A)
This is accomplished by introducing an extra hydrogen
bond to the water molecule that interacts only with residues
155{18} and 156{19} in wild-type FVIIa (Fig 1B,C)
Substitution of Asp for Val at position 158{21} would not
be expected to affect the activity of FVIIa unless Gln is
simultaneously present at position 298{156} to allow the
establishment of a hydrogen bond between the two
introduced side chains that in turn stabilizes the inserted
N-terminus (Fig 1B) An effect of the V158D mutation
becomes evident only after simultaneous replacement of
Glu296by Val, presumably due to electrostatic repulsion
between Asp at position 158 and Glu at position 296 In
addition, according to the structure of zymogen FVII [8],
the change at position 296{154} (Glu to Val) eliminates
hydrogen bonds between the Glu side chain and the
backbone carbonyls of residues 158{21} and 159{22} This
would remove an obstacle for the formation of a salt bridge
between the N-terminal residue 153{16} and Asp343{194}
as well as for the b strand reregistration that appears to be
required for FVIIa to attain its active conformation
Together, the three mutations result in a highly active
FVIIa molecule that is more comfortable in the active b
strand registration and with a buried N-terminus
Moreover, the mentioned b strand B2 and the preceding loop contain Glu296{154} and Arg290{147} which have been shown to be important for FX activation [25,27] This might explain why an ordering of this region selectively increases the proteolytic activity more than the amidolytic activity In accordance with this, displacement of this region
by a peptide exosite inhibitor causes a larger effect on the proteolytic activity of FVIIa than on its amidolytic activity [5]
A C K N O W L E D G E M E N T
We thank Anette Østergaard and Helle Bak for excellent technical assistance.
R E F E R E N C E S
1 Pedersen, A.H., Nordfang, O., Norris, F., Wiberg, F.C., Chris-tensen, P.M., Moeller, K.B., Meidahl-Pedersen, J., Beck, T.C., Norris, K., Hedner, U & Kisiel, W (1990) Recombinant human extrinsic pathway inhibitor Production, isolation, and character-ization of its inhibitory activity on tissue factor-initiated coagu-lation reactions J Biol Chem 265, 16876–16793.
2 Bode, W., Brandstetter, H., Mather, T & Stubbs, M (1997) Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C Thromb Haemostasis 78, 501–511.
3 Pike, A.C.W., Brzozowski, A.M., Roberts, S.M., Olsen, O.H & Persson, E (1999) Structure of human factor VIIa and its implications for the triggering of blood coagulation Proc Natl Acad Sci USA 96, 8925–8930.
4 Kemball-Cook, G., Johnson, D.J.D., Tuddenham, E.G.D & Harlos, K (1999) Crystal structure of active site-inhibited human coagulation factor VIIa (des-Gla) J Struct Biol 127, 213– 223.
5 Dennis, M.S., Eigenbrot, C., Skelton, N.J., Ultsch, M.H., Santell, L., Dwyer, M.A., O’Connell, M.P & Lazarus, R.A (2000) Peptide exosite inhibitors of factor VIIa as anticoagulants Nature
404, 465–470.
6 Banner, D.W., D’Arcy, A., Che`ne, C., Winkler, F.K., Guha, A., Konigsberg, W.H., Nemerson, Y & Kirchhofer, D (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor Nature 380, 41–46.
7 Zhang, E., St Charles, R & Tulinsky, A (1999) Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant J Mol Biol 285, 2089–2104.
8 Eigenbrot, C., Kirchhofer, D., Dennis, M.S., Santell, L., Lazarus, R.A., Stamos, J & Ultsch, M.H (2001) The factor VII zymogen structure reveals reregistration of b strands during activation Structure 9, 627–636.
9 Persson, E., Kjalke, M & Olsen, O.H (2001) Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity Proc Natl Acad Sci USA 98, 13583–13588.
10 Petrovan, R.J & Ruf, W (2001) Residue Met156contributes to the labile enzyme conformation of coagulation factor VIIa J Biol Chem 276, 6616–6620.
11 Persson, E., Bak, H & Olsen, O.H (2001) Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity J Biol Chem 276, 29195–29199.
12 Thim, L., Bjoern, S., Christensen, M., Nicolaisen, E.M., Lund-Hansen, T., Pedersen, A.H & Hedner, U (1988) Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells Biochemistry 27, 7785–7793.
13 Freskga˚rd, P.-O., Olsen, O.H & Persson, E (1996) Struc-tural changes in factor VIIa induced by Ca 2+ and tissue factor
Trang 6studied using circular dichroism spectroscopy Protein Sci 5,
1531–1540.
14 Persson, E & Nielsen, L.S (1996) Site-directed mutagenesis but
not c-carboxylation of Glu-35 in factor VIIa affects the association
with tissue factor FEBS Lett 385, 241–243.
15 Persson, E., Nielsen, L.S & Olsen, O.H (2001) Substitution of
aspartic acid for methionine-306in factor VIIa abolishes the
allosteric linkage between the active site and the binding interface
with tissue factor Biochemistry 40, 3251–3256.
16 Butenas, S., Lawson, J.H., Kalafatis, M & Mann, K.G (1994)
Cooperative interaction of divalent metal ions, substrate, and
tissue factor with factor VIIa Biochemistry 33, 3449–3456.
17 Persson, E & Petersen, L.C (1995) Structurally and functionally
distinct Ca 2+ binding sites in the c-carboxyglutamic
acid-con-taining domain of factor VIIa Eur J Biochem 234, 293–300.
18 Wildgoose, P., Foster, D., Schiødt, J., Wiberg, F.C., Birktoft,
J.J & Petersen, L.C (1993) Identification of a calcium binding site
in the protease domain of human blood coagulation factor VII:
Evidence for its role in factor VII–tissue factor interaction.
Biochemistry 32, 114–119.
19 Petrovan, R.J & Ruf, W (2002) Role of
zymogenicity-determin-ing residues of coagulation factor VII/VIIa in cofactor interaction
and macromolecular substrate recognition Biochemistry 41, 9302–
9309.
20 Perera, L., Darden, T.A & Pedersen, L.G (2002) Predicted
solution structure of zymogen human coagulation FVII J
Com-put Chem 23, 35–47.
21 McCallum, C.D., Hapak, R.C., Neuenschwander, P.F., Morris-sey, J.H & Johnson, A.E (1996) The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor A fluorescence energy transfer study J Biol Chem 271, 28168–28175.
22 Huang, Q., Neuenschwander, P.F., Rezaie, A.R & Morrissey, J.H (1996) Substrate recognition by tissue factor-factor VIIa Evidence for interaction of residues Lys165and Lys166of tissue factor with the 4-carboxyglutamate-rich domain of factor X.
J Biol Chem 271, 21752–21757.
23 Kirchhofer, D., Lipari, M.T., Moran, P., Eigenbrot, C & Kelley, R.F (2000) The tissue factor region that interacts with substrates factor IX and factor X Biochemistry 39, 7380–7387.
24 Zhong, D., Bajaj, M.S., Schmidt, A.E & Bajaj, S.P (2002) The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor J Biol Chem 277, 3622–3631.
25 Dickinson, C.D., Kelly, C.R & Ruf, W (1996) Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa Proc Natl Acad Sci USA 93, 14379–14384.
26 Dickinson, C.D & Ruf, W (1997) Active site modification of factor VIIa affects interactions of the protease domain with tissue factor J Biol Chem 272, 19875–19879.
27 Ruf, W (1994) Factor VIIa residue Arg290is required for efficient activation of the macromolecular substrate factor X Biochemistry
33, 11631–11636.